FDA Approved: FILSPARI — Original Application (Travere Therapeutics, Inc.)

View source ↗

Summary

FDA grants original approval for FILSPARI (sparsentan) from Travere Therapeutics for the treatment of focal segmental glomerulosclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis

Drugs mentioned

• FILSPARI (SPARSENTAN)

Snippet

ORIG AP for FILSPARI (SPARSENTAN)